Institution: The Federal Reserve to Downplay Temporary Inflation Impact from Tariffs
Nordea Bank points out that while risks are rising, the Federal Reserve is waiting for more clarity. Trade policy and economic outlook are seen as extremely uncertain, and the Fed hopes to wait for more definitive results. The market interprets this information as slightly hawkish, further reducing the likelihood of a rate cut at the June meeting. We agree with this market shift but expect the Fed to ultimately focus on supporting economic growth and ignore the temporary rise in inflation. If long-term inflation expectations remain within a controllable range and align with the inflation target, the Fed should be able to overlook the temporary inflation shock caused by tariffs.
There is also a possibility that the short-term impact of tariff uncertainty on the economy will exceed current expectations. However, for now, the Fed believes the move has a limited impact on the economy, and there are signs of some progress in trade negotiations. Inflation remains above target and is expected to start rising again due to tariffs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

